By: shaggydogs
01 Apr 2004, 09:10 AM EST
Msg. 145440 of 145456
Jump to msg. #  
OT: More on Naked Shorting: USXP vs. SEC

Universal Express Questions SEC Actions
Thursday April 1, 8:30 am ET

NEW YORK, April 1 /PRNewswire-FirstCall/ -- Universal Express, Inc. (OTC Bulletin Board: USXP - News) President & CEO, Richard A. Altomare, stated, "It's a classic David vs. Goliath case. We have respectfully waited without response from the SEC to the lawsuit we first filed against it for unconstitutional abuse of the powers given to it by Congress. In the meantime, the SEC resorts to negative publicity by attacking us in the press, rather than using the federal court system to determine the merits of our complaints. It also resorts to the highly unusual, if not improper, action of filing its own lawsuit against us in New York, rather than in the same federal court where we filed our lawsuit first.

"The SEC's accusations against our Company, its Chairman, its General Counsel, and numerous outside consultants that courageously helped to build this fine Company during naked short selling attacks, are unfounded. The SEC seems intent on maligning the messengers and assisting the naked short sellers by creating negative press on our Company more than defending against our accusations filed in the Miami federal court.

"This case will be heard in a courtroom, not in the media. Unlike the SEC, Universal Express has not inappropriately resorted to news releases detailing our complaints of rogue agent interference, collusion, SEC improper behavior and unconstitutional conduct, nor will we. We will keep faith with our judicial system and prove the misconduct in our lawsuit, rather than pontificate to the press.

"When we filed the initial lawsuit, USXP had presented over 50 formal quarterly and annual reports, and hundreds of press releases without review, question or comment by the SEC. We went without even a letter of reprimand or phone call for 14 years. We ask the public and our supporters: don't you think it untoward that, only days after our lawsuit against the SEC is filed and made public, USXP was accused retroactively for press releases, fundings and quarterly contents, and whatever else the SEC hopes will deter others from questioning its unregulated authority and joining in on our fight to outlaw and ban the naked short selling of publicly traded stocks?

"We stand behind our lawsuit. Despite the SEC's inappropriate accusations, improper behavior and inappropriate and unfounded response against one of the smaller developing public companies, we will wait until the case is heard," Mr. Altomare added. "According to the SEC, billions of shares of this company's stock have traded. If that trading happened because of one or more press releases or funding, as the SEC alleges, where are the certificates, we rhetorically ask," posed Mr. Altomare. "When all is said and done and all of the SEC documents to be produced are disclosed, the truth, not character attacks, will be told.

"Seemingly undefeatable adversaries are often defeated by their own actions. Our trading system relies on the professionalism and consistent objectivity of its regulators. When did our regulators become participants in the scandalous process of naked short selling by endeavoring to intimidate its critics by resorting to verbal hostility, unfair utilization of the press and invoking fear?

"Universal Express is a popular and innovative developing company that would have benefited from the on-going regulatory guidance of the Security and Exchange Commission during our growth. Whenever we called the SEC for assistance against naked short sellers, we were ignored. After our two consecutive successes in court against naked short selling schemes tied to other fraudulent conduct -- totaling over $526,000,000 -- we became an SEC target. All the SEC power and legal strength will not drown out the overdue voices of American shareholders and developing companies, trying to create American jobs, while being hurt by a regulatory trading system that is not protecting its developing companies. This time, a court of law will hear words of those victimized by the scandalous schemes and the even more scandalous ignoring of those schemes by the SEC. That's the case. Plain and simple," concluded, Richard A. Altomare.

By: kevtod
01 Apr 2004, 10:22 AM EST
Msg. 145456 of 145458
(This msg. is a reply to 145439 by SUE32073.)
Jump to msg. #  
Sue- Although the claim is/was that the Bahamas plant was up to par on FDA requirements, the plant was never inspected or FDA certified. Had the HPV topical trials continued, and the product continued to be manufactured at the Freeport plant, the FDA would have most likely inspected the plant before Phase II, but certainly before Phase III. I did have communication with the FDA on this point, and that is what I was told by them. I probably still have the documentation if required.

(As a side note: We have been "currently negotiating the sale of the Bahamian facility" since December 2002.)

Although the timeline for inspection of the Yonkers plant wil be set by the FDA, it is not unreasonable to presume that they would apply the same standards to Yonkers as they did to the Freeport plant.....

Hope this helps....




Insynq Inc (BB: ISYN)
ISYN Quote | ISYN Msg Board | ISYN LiveCharts | ISYN Chart | ISYN News | ISYN Company Info | ISYN I-Watch | ISYN Insider | ISYN Analyst Recs | ISYN Top Holders
« ISYN Message list  |  Reply to msg.  |  Post new msg.   « Older | Newer »   
By: rett_i_dass
01 Apr 2004, 10:36 AM EST
Msg. 3778 of 3778
Jump to msg. #  
Naked ShortSelling ‘Officially’ Ends Today, But Not Without a Struggle / FinancialWire®

April 1, 2004. (FinancialWire) Today’s the deadline set by the NASD for U.S. marketmakers and brokerages such as Olde / H&R Block (NYSE: HRB) and Charles Schwab (NYSE: SCH), to implement the new NASD short-selling regulations that reportedly will cut the lifelines of naked short-sellers, but if that happens, manipulative trading is not going slowly into the sunset.
Lifeline Biotechnologies (OTCBB: LBTT) has accused market makers of a “slow down” in processing buy orders to allow short sellers to cover, and Paid, Inc. (OTCBB: PAYD) says that of the approximately 76 million shares that have changed hands between December 2003 and March 23, 2004, there has been a documented failure-to-deliver of approximately 72.8 million shares.
Interestingly, the company could not previously get this information from the Depository Trust and Clearing Corp., known as the DTC, but is now able to track the non-deliveries via its own transfer agent.
Recently, renowned columnist, Jack Anderson, who writes the “Washington Merry-Go-Round,” alleged that much of the naked short selling in small cap stocks drains small U.S. companies of their market caps and their small investors of their nest-eggs specifically to funnel money into terrorist hands, a sort of double-whammy against the American capitalist system.
According to the Wall Street Journal, J.P. Morgan Chase, which declined to comment on any possible rule violations, said it has been working with regulators to tighten its standards. "We agree with regulators that financial institutions should continually raise standards on know-your-customer policies, and have worked with them to ensure that we tighten ours and strive to exceed the law," WSJ quoted a bank spokeswoman.
“The USA Patriot Act, adopted in October 2001, expanded the scope of U.S. money-laundering rules in order to make it harder for terrorists to move money without attracting attention. It includes beefed-up know-your-customer requirements for some financial institutions, according to some legal experts” said the U.S. financial newspaper.
Recently, leading market makers and brokers named in various lawsuits and other actions, including FleetBoston (NYSE: FBF), Goldman, Sachs & Co. (NYSE: GS), H. Myerson & Co., Inc. (NASDAQ:MHMY), Olde / H&R Block (NYSE: HRB), Charles Schwab (NYSE: SCH), Toronto-Dominion’s (NYSE: TD), TD Waterhouse Group and vFinance, Inc. (OTCBB: VFIN). A.G. Edwards, Inc. (NYSE: AGE), Ameritrade Holding Corp. (NASDAQ:AMTD), Deutsche Bank AG (NYSE: DB), and ETrade Group, Inc. (NYSE: ET), were given a “reprieve” until April 1 to comply with new short-selling market regulations imposed by the NASD after the SEC had “sat on” the NASD request to plug material loopholes for almost 2-1/2 years.
For some in the industry, the fact that the new date coincides with “April Fool” was not lost.
The NASD noticed its members that it is “delaying the effective date of amendments to Rule 3370 (Prompt
Receipt and Delivery of Securities—the "Affirmative Determination" Rule) approved by the SEC in November 2003, until April 1, 2004.
“The amendments expand the scope of the affirmative determination requirements to include orders received from broker/dealers that are not members of NASD ("non-member broker/dealers"). The effective date of the amendments originally was April 1, 2004,” said the notice.
The proposed and now delayed rule is on the web at
The rule itself, while welcomed by small companies and their shareholders in the U.S., nevertheless raised an outcry because the NASD’s request to put it into effect had set on a shelf at the SEC since 2001.
Recent wrist slaps have involved Falcon Research, Inc., fined $10,000, SG Cowen Securities Corporation, fined $230,000, and Sterne, Agee & Leach, Inc., fined $35,000.
Meanwhile, CBS Marketwatch, a venture between Marketwatch (NASDAQ: MKTW) and Viacom’s (NYSE: V) CBS unit, has suggested that victims of securities fraud may be able to file for theft claims on tax returns instead of capital losses.
The scandal has embroiled hundreds of companies and dozens of brokers and marketmakers, in a web of internaitional intrigue, manipulative short-selling and cross-border accusations and denials.
Comments on Regulation SHO ended January 5, and may be viewed at .
Some 122 companies, including 13 brokers, such as FleetBoston (NYSE: FBF), Goldman, Sachs & Co. (NYSE: GS), H. Myerson & Co., Inc. (NASDAQ:MHMY), Olde / H&R Block (NYSE: HRB), Charles Schwab (NYSE: SCH), Toronto-Dominion’s (NYSE: TD), TD Waterhouse Group and vFinance, Inc. (OTCBB: VFIN). A.G. Edwards, Inc. (NYSE: AGE), Ameritrade Holding Corp. (NASDAQ:AMTD), Deutsche Bank AG (NYSE: DB), and ETrade Group, Inc. (NYSE: ET), have been embroiled for over a year in a raging controversy
The remaining 109 companies among the 122 named to date have issued press releases or been named in the media as having been victimized, or as taking various actions, either alone or in concert with other companies, to oppose manipulative trading in the form of illegal naked short selling. The actions have ranged from lawsuits to withdrawals and threatened withdrawals from the electronic trading system managed by the Depository Trust & Clearing Corp., to withdrawals from toxic financings, to the issuance of dividends or name changes designed to squeeze manipulators, to joining associations or networks or to contacting regulatory authorities to provide documentation of abuses or otherwise complain.
The complete list of those 108 companies include Advanced Viral Research Corp. (OTCBB: ADVR), AdZone Research, Inc. (OTCBB: ADZR), Amazon Natural Treasures (OTC: ANTD), America's Senior Financial Services (OTCBB: AMSE), American Ammunition, Inc. (OTCBB: AAMI), AngelCiti Entertainment (OTCBB: AGLC), ATSI Communications, Inc. (OTC: ATSC), Federal Agricultural Mortgage / Farmer Mac (NYSE: AGM) Allied Capital (NYSE: ALD), American Motorcycle (OTC: AMCYV), American International Industries (OTCBB: AMIN), Ameri-Dream (OTC: AMDR), Adirondack Pure Springs Mt. Water Co. (OTCBB: APSW), ATSI Communications, Inc. (OTC: ATSC) Bluebook International (OTCBB: BBIC), Blue Industries (OTCBB: BLIIV), Bentley Communications (OTCBB: BTLY), BIFS Technologies Corporation (OTCBB: BIFT), Biocurex (OTCBB: BOCX). Broadleaf Capital Partners, Inc. (OTCBB: BDLF), Chattem, Inc. (NASDAQ:CHTT), Critical Home Care (OTCBB: CCLH), Composite Holdings (OTC: COHIA), CyberDigital, Inc. (OTCBB: CYBD). Diamond International Group (OTCBB: DMND), Dobson Communications Corp. (NASDAQ:DCEL), Eagle Tech Communications (OTC: EATC), Edgetech Services (OTCBB: EDGH);
Also, Endovasc Ltd. (OTCBB: EVSC), Enviro-Energy Corporation (OTCBB: ENGY), Environmental Products & Technologies (OTC: EPTC), Environmental Solutions Worldwide, Inc. (OTCBB: ESWW), EPIXTAR Corp. (OTCBB: EPXR), eResearchTechnologies, Inc. (NASDAQ:ERES), Flight Safety Technologies (OTCBB: FLST), Freddie Mac (NYSE: FRE), FreeStar Technologies (OTCBB: FSRCE), Front Porch Digital,
Inc. (OTCBB: FPDI), Geotec Thermal Generators, Inc. (OTCBB: GETC), Genesis Intermedia (OTC: GENI), GeneMax Corp. (OTCBB: GMXX), Global Explorations Inc (OTC: GXXL), Global Path (OTCBB: GBPI), GloTech Industries, Inc. (OTCBB: GTHI), Green Dolphin Systems (OTCBB: GLDS), Group Management (OTCBB: GPMT), Hop-On (OTC: HPON), H-Quotient, Inc., (OTCBB: HQNT), Hyperdynamics Corp. (OTCBB: HYPD), International Biochem (OTCBB: IBCL), Intergold Corp. (OTCBB: IGCO), International Broadcasting Corporation (OTCBB: IBCS), InternetStudios, Inc. (OTCBB: ISTO), ITIS Holdings (OTCBB: ITHH), Investco Corp. (OTCBB: IVCO), Lair Holdings (OTC: LAIR), Lifeline BioTechnologies Inc. (OTC: LBTT), Life Energy & Technology (OTCBB: LETH), MBIA (NYSE: MBI);
Also, MegaMania Interactive (OTC: MNIA), MetaSource Group, Inc. (OTCBB: MTSR), (OTC: MIDS), Make Your Move (OTCBB: MKMV), Medinah Minerals (OTC: MDMN), MSM Jewelry Corp. (OTC: MSMC), Nanopierce Technologies, Inc. (OTCBB: NPCT), Nutra Pharmaceutical (OTCBB: NPHC), Nutek (OTCBB: NUTK), Navigator Ventures (OTC: NVGV), Orbit E-Commerce, Inc. (OTCBB: OECI), Pitts & Spitts (OTC: PSPP), Sales OnLine Direct (OTCBB: PAID), Pacel Corp. (OTCBB: PACC), PayStar Corporation (OTC: PYST), Petrogen Corp. (OTCBB: PTGC), Pinnacle Business Management (OTC: PCBM), Premier Development & Investment, Inc. (OTCBB: PDVN),, Inc. (OTC: PRIM), Phlo Corporation (OTCBB: PHLC), Resourcing Solutions (OTC: RESG), Reed Holdings (OTC: RDHC), Rocky Mountain Energy Corp. (OTCBB: RMECE), RTIN Holdings (OTCBB: RTNHE), Saflink Corp. (NASDAQ:SFLK), Safe Travel Care (OTCBB: SFTVV), Sedona Corp. (OTCBB: SDNA);
Also, Sionix Corp. (OTCBB: SINX), Sonoran Energy (OTCBB: SNRN), Starmax Technologies (OTC: SMXIF), Storage Suites America (OTC: SSUA), Suncomm Technologies (OTC: STEH), Sports Resorts International (NASDAQ:SPRI), Technology Logistics (OTC: TLOS), Swiss Medica, Inc. (OTCBB: SWME), Ten Stix, Inc. (OTCBB: TNTI), Tidelands Oil (OTCBB: TIDE), Titan Construction (OTC: TTCS), Trezac Corp. (OTCBB: TRZAV), Universal Express, Inc. (OTCBB: USXP), Valesc Holdings, Inc. (OTCBB: VLSHV), Vega Atlantic (OTCBB: VGAC), Viragen (AMEX: VRA), Viragen International (OTCBB: VGNI), Vista Continental Corporation, (OTCBB: VICC), Viva International (OTCBB: VIVI), Vtex Energy (OTCBB: VXENE) and Wizzard Software (OTCBB: WIZD), (OTC: WTSW) and Y3K Secure Enterprise Software, Inc. (OTCBB: YTHK).
Earlier in 2003, the SEC fined Rhino Advisors, Inc., $1 million for its representation of Amro International in the financing and manipulation of Sedona Corp. Amro, also known as AMRO, was registered in Panama, a secretive offshore haven, but was not named in the SEC settlement. Another 60 public companies may have been manipulated by the fined Rhino Advisors and its indicted principals, or its funding apparatus, Amro.
These include:
All American Food Group Inc (OTC: AAFGQ), Amanda Co Inc (OTC: AMNA), Antra Holdings (OTC: RECD), Aquis Communications Group Inc (OTCBB: AQUIS), Avanir Pharmaceuticals (AMEX: AVN), Bionutrics Inc (OTC: BNRX), Brilliant Digital Entertainment Inc (AMEX: BDE), Bravo! Foods International Corp. (OTCBB: BRVOE), Butler National Corp (NASDAQ: BUTL), Calypte Biomedical Corp (OTCBB: CYPT), Chemtrak Inc/DE (OTC: CMTR), Clicknsettle Com Inc (OTCBB: CLIK), Corporate Vision Inc (OTC: CVIA), Crown Laboratories Inc/DE (OTC: CLWB), Dental Medical Diagnostic Systems Inc (OTC: DMDS), Detour Media Group Inc (OTC: DTRM),
Also, Digital Privacy Inc/DE (OTC: DGPV), Senior Services Inc (OTC: DISS), International Inc (OTC: DYNX), Endovasc Ltd Inc (OTCBB: EVSC), Esynch Corp/CA (OTCBB: ESYN), Focus Enhancements Inc (NASDAQ: FSCE), Frederick Brewing Co (OTC: FRBW), Greystone Digital Technology Inc (OTC: GSTN), Havana Republic Inc/FL (OTCBB: HVNR), Henley Healthcare Inc (OTC: HENL), Hollywood Media Corp (NASDAQ: HOLL), Ibiz Technology Corp (OTCBB: IBZT), Diagnostic Systems Inc/FL (OTCBB: IMDS), Imaging Technologies (OTCBB: IMTO), Integrated Surgical Systems Inc (OTCBB: RDOC),
Also, Interferon Sciences Inc (OTC: IFSC), Interiors Inc (OTC: ITRNA), Laminaire Corp (OTC: THMZ), Medisys Technologies Inc (OTC: SCEP), Milestone Scientific Inc/NJ (AMEX: MS), Nevada Manhattan Group Inc (OTC: NVMH), Innovations Inc (OTCBB: NTGE), Systems Group (OTC: OSYM), Pacific Systems Control Technology Inc (OTCBB: PFSY), Professional Transportation Group Ltd Inc (OTC: TRUC), Rnethealth Inc (OTC: RNTT),
Also, Sand Technology Inc (NASDAQ: SNDT), Sedona Corp (OTCBB: SDNA), Silverado Foods Inc (OTC: SVFO), Stockgroup Information Systems (OTCBB: SWEB) Surgilight Inc (OTC: SRGL), Tasty Fries Inc (OTCBB: TFRY), Tech Laboratories Inc (OTCBB: TCHL), Teltran International Group Ltd (OTC: TLTG), Titan Motorcycle Co of America Inc (OTC: TMOTQ), Trans Energy Inc (OTCBB: TSRG), Motorcycle Co (OTC: UMCC), Universal Communication Systems Inc (OTCBB: UCSY), Medical Systems Inc (OTC: UMSI), Vianet Technologies Inc (OTC: VNTK),Viragen Inc (AMEX: VRA), Webcatalyst Inc (OTC: WBCL), Worldwide Wireless Networks Inc (OTCBB: WWWNQ), and ZAP (OTCBB: ZAPZ).

(Voluntary Disclosure: ST Rating- Strong Buy; LT Rating- Strong Buy)

By: shaggydogs
01 Apr 2004, 03:06 PM EST
Msg. 145477 of 145552
Jump to msg. #  
After speaking with ADVR's IR/PR people, the company says that all the information in the 10-K is factually accurate and they continue to stand by their statement that the trial in Israel involving cachectic AIDS patients will be completed during the 2nd quarter [April 1 - June 31] 2004.

IMO, this means one of two things:
1. ADVR believes they can still recruit and complete testing of 7 more patients during the present fiscal quarter, or
2. ADVR will complete and report on the trial with less then 30 patients enrolled.

Kevin (or anyone else who knows anything about clinical trials), is it possible to complete the trial without recruiting the full 30 patients. For example, if we were to assume that all 23 patients enrolled responded positively to the AVR118 treatment, could ADVR complete/end and report on the trial since whether it is 23 out 30 or 30 out of 30 patients showing efficacy, statistical significance would have been achieved? Or is this just not realistic?
By: shaggydogs
01 Apr 2004, 04:07 PM EST
Msg. 145486 of 145552
(This msg. is a reply to 145457 by SUE32073.)
Jump to msg. #  
Funny stuff, in a way. The Freeport plant was never inspected or FDA certified. Doesn't this mean that every one who has ever been injected with Reticulose/AVR118 has used product that was manufactured by a non FDA certified manufacturing facility.

Everyone! With no reported toxic reactions! Everyone, even those cancer patients treated by Dr. D'Olimpo at Northshore. Everyone, even those 23 patients involved in the Israeli trials. Yes, everyone who has ever ordered product out of Canada.

Why? Because the people associated with Reticulose have know for years [≈70] how to manufacture an effective, non toxic and sterilized product. They've known well before any bureaucrat even had a glimmer in his eye for the establishment of an FDA.

By: shemp1248
01 Apr 2004, 04:11 PM EST
Msg. 145487 of 145552
(This msg. is a reply to 145477 by shaggydogs.)
Jump to msg. #  
Shaggy., This drug will end up producing multiple indications for the medical folks to ponder when treating patients. I think the key here is to have a clear understanding of what the FDA will need to get this drug off and running. I feel that the scientists working anywhere near this formula have concluded this switch-type immune system drug can and will be not only helpful, but safe. I would love to know how many shares are owned by family members of the FDA employees closely tied to the progression of ADVR's progress. I am not the only person in the medical community that feels this drug is the next huge blockbuster, and this could be the reason ADVR is holding off from asking a bigger company to join up. This formula will be available to doctors very soon and the question will be how the company can maximize their financial potential. Instead of letting the doctors have one drug with many indications, they may choose to alter a molecule or two and send out multiple drugs with different trade names. This can be done without any changes in safety or efficiency, and allow for the Oncologist to treat their patients, and the Neurologist to help their MS patients with different trade names from the same company. I would think ADVR is setting things up this way and has communicated this with the FDA in order to avoid problems once this drug is an OK. I am hoping this is the reason for the delays and irregular path this company seems to take at times. The path ADVR has to take is unique in that most small Biotechs. find a formula that is good, but has finite indications with a few side effects, and the larger Pharm. bring their drugs to market without much hype since they are already big and have multiple dollars and products. ADVR is comming out of the closet with a huge formula that has an infinite potential, and may push this company way up the ladder. Thanks, Mike

(Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy)

By: kevtod
01 Apr 2004, 09:46 PM EST
Msg. 145546 of 145552
(This msg. is a reply to 145477 by shaggydogs.)
Jump to msg. #  
Shag- It is quite realistic. The trial is complete when ADVR says it is complete. There is more than ample precedence for ending a trial prior to meeting the original protocols intended quota.

It goes without saying that the larger the trial, the more weight that can be given to the statistical significance.

As far as using the data in support of an IND to be filed with the FDA.....more would be better. I know that it sounds odd, and I'm sure that someone with much more experience & knowledge will try to correct me, but 6 out of 10 is not the same as 60 out of 100, which is not the same as 600 out of 1000.....

But, I'm sure that none of this will matter, because AVR118 is sure to be 100% effective 100% of the time.....TIC.....

FWIW- The company can, in good faith, claim that the trials are on schedule right up until the 31st of June.....What they are not telling us, (although I did see some mention in passing), is that the extrapolation of the data will take several months beyond that.....

So, I remain a happy camper wherein my expectations of published Phase I/IIa results out of Israel will be forthcoming by January 2005. Anything sooner than that will be a bonus in my book......

Best to you & your son Shag, miss sparring with you.....

It's All Well & Good.....-kevin

By: kevtod
01 Apr 2004, 09:49 PM EST
Msg. 145547 of 145552
Jump to msg. #  
In the 4/9/04 AIDS article titled "Granule-dependent mechanisms
of lysis are defective in CD8 T cells of HIV-infected, antiretroviral
therapy-treated individuals," Trabattoni et al. (Mario Clerici is senior
author) state:

"Thus, ART fails to restore HIV-specific CTL; moreover, the activity of
HIV-specific CTL decreases after ART-induced suppression of HIV. This
results in a rapid rebound of HIV replication upon interruption of ART
even in patients in whom plasma viraemia had been undetectable for
prolonged periods of times. It is nevertheless strong in HIV-infected
long-term non-progressors in whom viraemia is low but detectable.
A potent HIV-specific CTL response is also detected in asymptomatic
HIV-infected individuals who have chosen not to undergo ART but
nevertheless control viral replication."

"We performed the same analyses in CMV-stimulated PBMC and observed that
reduced perforin and granzymes expression and synthesis are also
detected in CMV-specific CD8 lymphocytes. These data reinforce the idea
that CD8 defects are not antigen-specific but rather are associated with

"Why are CTL defective in ART-treated individuals? The observation that
the low perforin-expression CD8+/27+/28- are only slightly increased in
treated patients does not justify our results. An alternate explanation
is that antiretroviral drugs directly interfere with the synthesis of
perforin and granzymes. Preliminary data obtain by culturing in vitro
PBMC of healthy individuals with antiviral drugs suggest that this
mechanism is probably involved in CTL impairment. Additional data
obtained in HIV-exposed health care workers undergoing ART-based
prophylaxis, show that perforin and granzymes are reduced in CD8 T
lymphocytes after 1 month of therapy (M. Cleric, et al., unpublished
results). The small number of individuals examined did not allow us to
verify whether these effects are associated with any particular drug
regimens (e.g., PI versus NNRTI). It will be of interest to verify if
such correlation exists in larger cohorts of patients."

"It was assumed that ART-induced HIV suppression would be associated
with immune recovery, allowing immune control over HIV replication. The
evidence that HIV rebounds once therapy is suspended negates this
theory. Our data demonstrate the presence of a functional impairment in
CTL of ART-treated patients and provide a rational basis justifying the
lack of immune control over HIV replication observed even in
successfully ART-treated individuals."


Trabattoni D, Piconi S, Biasin M, Rizzardini G, Migliorino M,
Seminari E, Boasso A, Piacentini L, Villa ML, Maserati R, Clerici M.
Granule-dependent mechanisms of lysis are defective in CD8 T cells of
HIV-infected, antiretroviral therapy-treated individuals. AIDS 2004 Apr

Department of Immunology, University of Milano, Milano, Italy.

Abstract: Background: HIV-specific cytotoxic T-cell (CTL) responses are
defective in HIV-infected patients undergoing antiretroviral therapy
(ART). This defect has been attributed to the decreased antigenic burden
secondary to ART-associated suppression of HIV-replication, and is
responsible for the rebounds of viraemia that occur when patients
interrupt therapy. CTL are stimulated by type 1 cytokines and can kill
targets via granule-dependent (perforin and granzymes) and -independent
(tumour necrosis factor-alpha, CD95) mechanisms.

Methods: Granule-dependent and granule-independent mechanisms of CTL
killing, as well as type 1 cytokine production by CD4 T cells, were
analysed in 57 chronically HIV-infected ART-treated or ART-untreated

Results: The results can be summarized as follows: the frequency of
gp160 (env)-specific interferon-gamma-secreting CD8 T lymphocytes
correlates positively with HIV viraemia in ART-treated and -untreated
patients; Env-specific perforin- and granzymes-expressing CD8 T
lymphocytes, and Env-stimulated perforin and granzymes mRNA, are reduced
in ART-treated patients independently of HIV viral load and of type 1
cytokine production; tumour necrosis factor-alpha production is
increased in ART-treated individuals; and Env-specific immature
CD8+28+27+ cells are only marginally augmented in ART-treated patients,
Similar results are observed in cytomegalovirus-specific CD8 T cells and
peripheral blood mononuclear cells.

Conclusions: A defect of CTL function that selectively affects the
granule-dependent mechanisms of lysis is observed in ART-treated
individuals. Because interferon-gamma production is higher in these
patients, this could be a defect primarily involving CTL. These data
suggest an independence of CD8 T-cell numbers and their lytic ability in
HIV-infected, ART-receiving patients. Immunomodulants are needed to
successfully treat HIV infection.
By: aven2002
01 Apr 2004, 10:13 PM EST
Msg. 145548 of 145552
(This msg. is a reply to 145547 by kevtod.)
Jump to msg. #  
Hi Kevtod,....."Immunomodulants are needed to
successfully treat HIV infection.
Well I am surely no Rocket Scientest but isn't this where AVR118 comes into the PICTURE!!.......GO GO GO ADVR....Aven1
By: leoclyde
01 Apr 2004, 10:31 PM EST
Msg. 145550 of 145552
Jump to msg. #  
From OTC News Alert:

NASD Regulation 3370 Goes Into Effect Today: Illegal Naked Shorts on the Run

For those of you who have been following this issue, I have an update. If you see some Bulletin Board stocks begin to trade a little crazy, it may be the result of this new regulation.

I have reported on this issue in four previous editions, and I have learned a new rule went into effect today which appears to be the answer to a problem which has plagued the microcap market for many years.

Illegal naked short sellers have been able to funnel trades into US markets through Canadian Brokerage firms to the detriment of many investors. US brokerage firms are regulated by both the SEC and the NASD. Canadian firms are not.

NASD Regulation 3370, entitled "Affirmative Determination Requirements" places the responsibility on the US Brokerage firms to determine if sellers who are non NASD member (coming from outside the US) can actually deliver the securities they are selling. If they cannot, the trade cannot be executed on their behalf.

The new NASD rule went into effect today, and rumor has it that illegal naked short sellers are scrambling to find a home for their positions. I don't believe they will be forced to cover existing shorts, but for future trading the loophole has been closed. Look for this to have a very positive effect on many microcap stock values.